Why isn’t the mainstream media talking about this more?
Millions of Americans have felt the sting of rising health care costs for years, but new numbers show some welcome relief at the pharmacy counter.
Prescription drug prices fell 3.1% over the past year, marking the steepest annual decline in more than six decades.
The White House says President Donald Trump’s aggressive push against high pharmaceutical prices is helping deliver the historic decline — and the administration wants Americans, especially seniors and families struggling with medical bills, to know about it.
For people living on Social Security, retirement savings or fixed incomes, lower prescription costs aren’t simply another economic statistic. They can mean more money left over for groceries, utilities, gasoline and other everyday expenses.
And Trump is making the issue a major part of his economic message ahead of the midterm elections.
Prescription Drug Prices See Historic Decline
Prescription medications have long been one of the most frustrating expenses facing American families.
Now, government inflation data show prescription drug prices falling 3.1% compared with a year earlier — the largest annual decline since 1963.
The Trump administration quickly highlighted the numbers as evidence that its strategy toward the pharmaceutical industry is producing results.
Trump entered office promising to challenge drug manufacturers over the significantly higher prices Americans often pay compared with consumers in other developed countries.
His administration has pursued what it calls a Most Favored Nation strategy designed to bring American prices closer to those available overseas.
The White House argues that Americans should no longer be forced to shoulder disproportionately high pharmaceutical costs while other wealthy countries negotiate lower prices.
Trump Turns Up the Heat on Big Pharma
Rather than relying solely on traditional negotiations in Washington, Trump has used the threat of tariffs and other government action to pressure major pharmaceutical manufacturers.
That pressure has resulted in a series of agreements with drug companies offering lower prices on certain medications.
The White House says Trump’s Most Favored Nation initiative has secured agreements with major pharmaceutical manufacturers intended to provide substantial savings on numerous drugs used by millions of patients.
The administration has also launched TrumpRx, an initiative aimed particularly at Americans who purchase certain medications directly rather than through insurance.
For seniors and other consumers facing high out-of-pocket prescription costs, the potential savings can be significant.
TrumpRx Targets Americans Paying Cash for Medicine
One of Trump’s most visible health care initiatives is TrumpRx.
The program is intended to make discounted cash prices easier for consumers to find on participating medications.
That distinction is important.
Americans with comprehensive prescription insurance may not necessarily receive the same benefit as someone paying directly for medication. But for people who are uninsured, underinsured or facing expensive prescriptions that aren’t adequately covered, cash discounts can potentially make a major difference.
Trump has repeatedly argued that competition and transparent pricing can help drive health care costs lower.
His administration believes TrumpRx gives consumers another option while increasing pressure on pharmaceutical companies to compete on price.
Pfizer Announces Major Prescription Discounts
Some of the biggest headlines have come from discounts announced on specific medications.
Pfizer agreed to participate in the TrumpRx initiative with substantial reductions on several drugs.
The menopause medication Duavee, for example, received a discount of approximately 85%, bringing its advertised cash price to roughly $30.
Toviaz, which is used to treat overactive bladder, also received an approximately 85% reduction, bringing its price to around $42.
Eucrisa, a prescription eczema treatment, received an approximately 80% discount, reducing its price to about $162 per tube.
The migraine treatment Zavzpret received roughly a 50% reduction, bringing the uninsured cash price to around $600 per month.
Xeljanz, which is prescribed for conditions including rheumatoid arthritis, received an approximately 40% discount.
Those figures also demonstrate why health care affordability remains such an important issue.
Even after a substantial percentage reduction, some specialty medications can still cost thousands of dollars.
Ozempic and Wegovy Prices Get Trump’s Attention
Trump has also focused on one of the fastest-growing areas of the pharmaceutical industry: GLP-1 medications.
Drugs including Ozempic and Wegovy have become widely known because of their use in treating diabetes and obesity.
Demand has exploded, but the medications can carry significant costs for patients without adequate insurance coverage.
The administration has highlighted agreements involving GLP-1 drugs as evidence that Trump’s pressure campaign can reach some of the most sought-after medications in America.
Lowering those prices could become increasingly important as more Americans discuss weight-loss medications with their doctors and insurance providers.
The administration has also pursued savings involving other expensive treatments, including fertility drugs.
What Lower Drug Prices Could Mean for Seniors
The issue may be especially important for America’s seniors.
Older Americans are generally more likely to use multiple prescription medications, making changes in drug prices particularly important for household budgets.
Someone living primarily on Social Security, a pension or retirement savings has limited flexibility when recurring medical expenses increase.
Lower prescription costs can therefore have consequences beyond the pharmacy.
Money saved on medications can potentially help cover food, electricity, property taxes, insurance premiums and other expenses that retirees face every month.
That’s one reason health care and prescription drug prices remain such powerful political issues among voters over 50.
There’s a Political Fight Over Who Deserves Credit
The White House is claiming Trump’s policies are helping drive the decline, but there is an important dispute over exactly what caused prescription prices to fall.
Medicare drug-price negotiations established under former President Joe Biden also took effect this year for 10 high-cost medications.
Some economists and health policy experts argue those negotiations are contributing to the decline.
Other factors, including the introduction of cheaper generic medications as patents expire, may also be affecting the overall numbers.
The Trump administration strongly rejects attempts to give Biden’s policies primary credit.
White House spokesman Kush Desai called that argument “idiotic and unfounded,” maintaining that Trump’s policies are producing meaningful savings for American patients.
The bottom line is that several changes are occurring simultaneously, making it difficult to assign the entire 3.1% decline to one government policy.
What isn’t disputed is the number itself: Americans are seeing the largest annual decline in prescription drug prices in more than 60 years.
Trump Wants Congress to Make Drug Savings Permanent
The next battle could happen on Capitol Hill.
Trump has called on Congress to codify parts of his prescription drug strategy, potentially making elements of the Most Favored Nation approach a more permanent part of federal policy.
That could turn prescription prices into an even larger issue during the midterm elections.
Republicans can point to declining drug prices as evidence that Trump’s economic agenda is producing tangible results.
Democrats, meanwhile, are likely to argue that Biden-era Medicare negotiations deserve substantial credit.
For voters, however, the political fight may matter less than what happens when they pick up their prescriptions.
Trump Expands His Affordability Message
Prescription drugs are only one part of Trump’s broader effort to convince Americans that his economic policies are improving household finances.
The president has also promoted tax relief affecting seniors and workers earning tips and overtime wages, along with provisions involving interest on qualifying loans for domestically produced vehicles.
Trump has additionally pointed to stock-market gains and their effect on retirement accounts, including 401(k)s and IRAs.
That message is clearly aimed in part at older Americans who are watching retirement savings, taxes, health care expenses and inflation particularly closely.
At the same time, Americans remain concerned about the broader cost of living, including gasoline, groceries, insurance and medical care.
Trump has argued that recent inflationary pressures connected to the Iran war will be temporary.
Health Insurance Companies Could Be Next
Big Pharma may not be Trump’s final target.
Trump has also indicated that he wants to put pressure on major health insurance companies and their executives as Americans continue struggling with premiums, deductibles and out-of-pocket medical expenses.
The president has argued that insurance companies should face greater scrutiny over profits while families struggle to afford coverage.
That could set up another major confrontation between the White House and one of America’s most powerful industries.
For Republicans, taking on pharmaceutical and insurance companies could also provide a populist message heading into the congressional elections: Washington should work for patients rather than powerful health care corporations.
The Bottom Line for American Families
There is plenty of political disagreement over who deserves credit, but the latest prescription drug numbers contain genuinely encouraging news.
Prescription drug prices are down 3.1% from a year ago, the largest annual decline in more than 60 years.
Trump says his pressure on pharmaceutical companies and his Most Favored Nation strategy are major reasons why.
Critics point toward Biden-era Medicare negotiations and other market forces.
The real test will come over the months and years ahead.
Will prescription prices continue falling?
Will Trump’s agreements produce deeper savings on more medications?
And most importantly, will ordinary Americans actually see noticeably smaller bills when they visit the pharmacy?
For millions of seniors and working families, that’s the number that matters most.
